Krystal Biotech (KRYS) Revenue (2023 - 2026)

Krystal Biotech's Revenue history runs 4 years deep, the most recent figure standing at $116.4 million for Q1 2026.

• In Q1 2026, Revenue rose 31.95% year-over-year to $116.4 million; the TTM figure through Mar 2026 stood at $417.3 million (up 25.14% YoY), while the FY2025 annual figure was $389.1 million, up 33.93% from the prior year.
• Revenue came in at $116.4 million for Q1 2026 at Krystal Biotech, up from $107.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $116.4 million in Q1 2026 to a low of $8.6 million in Q3 2023.
• A 4-year average of $77.0 million and a median of $88.2 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue jumped 879.91% in 2024 and gained 16.65% in 2025, its largest moves.
• Krystal Biotech's Revenue stood at $42.1 million in 2023, then jumped by 116.2% to $91.1 million in 2024, then advanced by 17.54% to $107.1 million in 2025, then rose by 8.64% to $116.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $116.4 million, $107.1 million, and $97.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison